z-logo
Premium
Effectiveness and safety of empagliflozin‐based quadruple therapy compared with insulin glargine‐based therapy in patients with inadequately controlled type 2 diabetes: An observational study in clinical practice
Author(s) -
Ku Eu Jeong,
Lee DongHwa,
Jeon Hyun Jeong,
Oh Tae Keun
Publication year - 2019
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.13476
Subject(s) - empagliflozin , medicine , type 2 diabetes , insulin glargine , diabetes mellitus , empa , type 2 diabetes mellitus , adverse effect , insulin , combination therapy , endocrinology , chemistry , mineralogy , electron microprobe
This open‐label, prospective study evaluated the effectiveness and safety of empagliflozin as add‐on therapy in inadequately controlled type 2 diabetes (T2D) patients (glycated haemoglobin [HbA1c], 7.5‐12%) who were already using three other types of orally active antidiabetic agents. A total of 268 T2D patients were enrolled and divided into two groups, empagliflozin (EMPA 25 mg/d, n  = 142) or insulin glargine (INS, n  = 126), respectively. After the treatment period of 24 weeks, HbA1c and fasting plasma glucose (FPG) were significantly reduced (HbA1c, P  = 0.004; FPG, P  = 0.008, respectively) in the EMPA group compared to the INS group. Also, EMPA treatment evoked a significant reduction in body weight ( P  < 0.001) and systolic blood pressure ( P  = 0.017) compared to the INS group. Hypoglycaemic adverse events were significantly higher in the INS group compared to the EMPA group ( P  = 0.001). In conclusion, this study demonstrated that a regimen comprising four different orally active antidiabetic agents, including EMPA, was effective and safe as a therapeutic strategy for treating T2D patients for glycaemic control and improvement of other cardiovascular and metabolic indices.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here